These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 890698)

  • 21. Treatment of locally advanced prostatic carcinoma with LHRH analogues: cytological, DNA-cytophotometrical, and clinical results.
    Borgmann V; al-Abadi H; Nagel R
    Am J Clin Oncol; 1988; 11 Suppl 1():S19-28. PubMed ID: 2968759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cancer of the prostate: estrogen therapy].
    Mauriac L; Richaud P; Mage P; Thomas L; Lamarche P
    Bull Cancer; 1986; 73(1):23-30. PubMed ID: 3779120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Therapy of prostatic carcinoma].
    Lichtenauer P; Ihmann E
    Dtsch Med J; 1972 Mar; 23(3):248-9. PubMed ID: 5036536
    [No Abstract]   [Full Text] [Related]  

  • 24. L-phenylalanine mustard, doxorubicin, and vincristine in advanced breast cancer: a pilot study.
    Tormey DC; Bull JM; Lipman ML
    Cancer Treat Rep; 1980; 64(8-9):1015-6. PubMed ID: 7448819
    [No Abstract]   [Full Text] [Related]  

  • 25. Prostate carcinoma response to cytotoxic therapy: in vivo resistance.
    Teicher BA; Kakeji Y; Ara G; Herbst RS; Northey D
    In Vivo; 1997; 11(6):453-61. PubMed ID: 9509295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ketoconazole in advanced prostate cancer.
    Percy LA
    Ann Pharmacother; 1992 Dec; 26(12):1527-9. PubMed ID: 1482810
    [No Abstract]   [Full Text] [Related]  

  • 27. LHRH-analogues therapy for metastatic prostate cancer.
    Debruyne FM; Fernandez del Moral P; Geboers AD
    Prog Clin Biol Res; 1988; 260():27-39. PubMed ID: 2966406
    [No Abstract]   [Full Text] [Related]  

  • 28. [Chemotherapy of prostatic cancer].
    Portnoĭ AS
    Vopr Onkol; 1985; 31(9):3-12. PubMed ID: 2931901
    [No Abstract]   [Full Text] [Related]  

  • 29. Optimal hormonal therapy for advanced prostatic carcinoma.
    Goktas S; Crawford ED
    Semin Oncol; 1999 Apr; 26(2):162-73. PubMed ID: 10597727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of prostatic cancer with an LH-RH analog].
    Fuse H; Zama S; Akimoto S; Shimazaki J; Murakami S; Igarashi T
    Hinyokika Kiyo; 1986 Aug; 32(8):1113-9. PubMed ID: 3098063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High dose melphalan and autologous marrow rescue in advanced epithelial ovarian carcinomas: a retrospective analysis of 35 patients treated in France.
    Viens P; Maraninchi D; Legros M; Oberling F; Philip T; Herve P; Plagne R; Dufour P; Bergerat JP; Guastalla JP
    Bone Marrow Transplant; 1990 Apr; 5(4):227-33. PubMed ID: 2337735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients.
    Oosterlinck W; Mattelaer J; Casselman J; Van Velthoven R; Derde MP; Kaufman L
    Acta Urol Belg; 1997 Oct; 65(3):63-71. PubMed ID: 9421938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
    Lukkarinen O; Kontturi M
    Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [High doses of MAP in the treatment of prostatic carcinoma in stage T3-T4. Four-year study].
    Laudi M; De Zan A; De Luca G; Pigato M; Pagliano G
    Minerva Urol; 1982; 34(3):171-6. PubMed ID: 7177068
    [No Abstract]   [Full Text] [Related]  

  • 35. Lycopene for advanced hormone refractory prostate cancer: a prospective, open phase II pilot study.
    Schwenke C; Ubrig B; Thürmann P; Eggersmann C; Roth S
    J Urol; 2009 Mar; 181(3):1098-103. PubMed ID: 19150092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined treatment (goserelin plus flutamide) versus monotherapy (goserelin alone) in advanced prostate cancer: a randomized study.
    Jurincic CD; Horlbeck R; Klippel KF
    Semin Oncol; 1991 Oct; 18(5 Suppl 6):21-5. PubMed ID: 1835139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A pilot study of low dose etoposide therapy for recurrenced prostate cancer in complicated over 75 years old stage D2 cases].
    Wada T; Onodera S; Tashiro K; Iizuka N; Asano K; Yanada S; Takeuchi H; Ohishi Y
    Gan To Kagaku Ryoho; 1996 Nov; 23(13):1851-4. PubMed ID: 8937498
    [No Abstract]   [Full Text] [Related]  

  • 38. Diagnosing leptomeningeal carcinomatosis with negative CSF cytology in advanced prostate cancer.
    Bernstein WB; Kemp JD; Kim GS; Johnson VV
    J Clin Oncol; 2008 Jul; 26(19):3281-4. PubMed ID: 18591564
    [No Abstract]   [Full Text] [Related]  

  • 39. The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostate.
    Scott WW; Gibbons RP; Johnson DE; Prout GR; Schmidt JD; Saroff J; Murphy GP
    Trans Am Assoc Genitourin Surg; 1976; 68():24-8. PubMed ID: 1030548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy of advanced prostatic cancer.
    Murphy GP
    Rev Surg; 1977; 34(2):75-87. PubMed ID: 854703
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.